Skip to content
Late-StageResearch compoundLimited evidence

TAK‑653 (Osavampator)

Experimental antidepressant candidate (AMPA enhancer) that met its main goal in a phase 2 human trial; not yet approved.

NootropicAmpakineMood SupportBDNFGlutamateAMPABDNF

Pharmacology

ClassAmpakine · Mood Support · BDNF
Primary targetAMPA receptor positive allosteric modulator (glutamate-dependent)
Targets3 receptor targets
Half-life33-48 h
OnsetHours (acute cortical), weeks (antidepressant)
EvidenceLimited evidence
Affected systemsGlutamateAMPABDNF

Contents

DETAILED OVERVIEW

What is TAK-653 (Osavampator)?

TAK-653 (osavampator) is an experimental drug candidate developed by the pharmaceutical company Takeda and studied against depression. It is not approved anywhere: in the USA it is in clinical development, and in the European Union it counts as a research chemical and is not on the market.

It strengthens the AMPA receptor, one of the receiving proteins for glutamate, the brain's stimulating messenger, but only where nerve cells are already signaling. In animal studies this led to a fast, ketamine-like antidepressant effect, without ketamine's intoxicating, mind-altering effects. It was well tolerated in healthy volunteers, and in a phase 2 trial it met its main goal as an add-on treatment for depression; development continues in phase 3. Headache was the most commonly reported problem, and in theory overstimulation and, in people prone to epilepsy, seizures are possible. There is no safety data for pregnancy and breastfeeding.

Mechanism

AMPA-PAM (glutamate-dependent)

Half-life

33-48 hours

Onset

Hours (acute cortical), weeks (antidepressant)

Legal status

Investigational, Phase 3, not approved anywhere

Receptor profile

  • AMPA receptorStrong
  • BDNF / synaptic responseModerate
  • Long-term potentiation (LTP)Moderate

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Overstimulation, agitation from amplified glutamatergic (AMPA) signaling
  • Headache (the most commonly reported unpleasant effect)
  • Sleep disturbance, heightened alertness if dosed late in the day
  • Theoretical seizure/convulsion risk in those predisposed to epilepsy (though the preclinical safety margin is wide and no convulsions occurred in human studies)
  • Limited human safety data: investigational, unapproved compound, full side-effect spectrum still unknown
  • Long half-life (33-48 h) gives a cumulative effect, steady state over several days

Contraindications · 4

  • Personal or family history of epilepsy/seizures (theoretical risk from glutamatergic potentiation)
  • Avoid combining with other strong glutamatergic or stimulant compounds (overstimulation risk)
  • Pregnancy and breastfeeding: no clinical safety data, avoid
  • Not an approved drug, investigational; not recommended for self-treatment of major depression without clinical supervision

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

TAK-653 is a drug candidate being developed by Takeda for depression, and it already hit its target goal in an early-stage human trial. It works by boosting brain signaling pathways that are already active, aiming for a fast, ketamine-like mood lift without the dissociative, mind-altering side effects. It has also shown cognitive-sharpening effects in studies and looked safe so far, but it is still in research/clinical trials, not an available product.

Telegram

Have a question about TAK‑653 (Osavampator)?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC19H23N3O3S
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.